← Back to headlines
Moderna and Merck's Personalized Cancer Vaccine Shows Positive Phase 3 Results
Moderna and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine in combination with Keytruda for melanoma patients. This breakthrough has led to a significant surge in Moderna's stock and highlights the growth potential for biotech in cancer treatment.
24 Aug, 00:50 — 24 Aug, 14:07
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (71/100)9 sources33/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left2
Left (2)
Yahoodelo
Center2
Center (2)
morocco-world-newsthestreet
Right5
Right (5)
wsjseeking-alphaBarron'sdie-pressestraits-times
Far R
Geographic diversity— 5 regions21/34
US5Morocco1Slovenia1Austria1Singapore1
Sources
Showing 5 of 9 sources
Barron'sHigh19h ago
Moderna’s Cancer Vaccine Breakthrough Reveals Growth Potential for Biotech - Barron's
Moderna’s Cancer Vaccine Breakthrough Reveals Growth Potential for Biotech Barron's
Read full article →YahooMostly Factual16h ago
A cancer vaccine years in the making just proved itself
Read full article →straits-timesMostly Factual1d ago
Moderna’s mRNA cancer vaccine breakthrough in melanoma - The Straits Times
Moderna’s mRNA cancer vaccine breakthrough in melanoma The Straits Times
Read full article →thestreet19h ago
A cancer vaccine years in the making just proved itself
Merck added billions in a single day after its Moderna-partnered cancer vaccine cleared a major hurdle.
By Peace Longe
Read full article →morocco-world-newsMixed16h ago
Merck And Moderna’s Personalized Cancer Therapy Shows Positive Phase 3 Results - Morocco World News
Merck And Moderna’s Personalized Cancer Therapy Shows Positive Phase 3 Results Morocco World News
Read full article →Coverage Timeline
First report: straits-times · 24 Aug, 00:50|Full coverage: 9 · 17h|Window: 17h
Left-leaningCenterRight-leaning
